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Glucagon-like peptide-1 modulates neurally evoked mucosal chloride
secretion in guinea pig small intestine in vitro
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Baldassano S, Wang G, Mulè F, Wood JD. Glucagon-like pep-
tide-1 modulates neurally evoked mucosal chloride secretion in
guinea pig small intestine in vitro. Am J Physiol Gastrointest Liver
Physiol 302: G352–G358, 2012. First published November 10, 2011;
doi:10.1152/ajpgi.00333.2011.—Glucagon-like peptide-1 (GLP-1)
acts at the G protein-coupled receptor, GLP-1R, to stimulate secretion
of insulin and to inhibit secretion of glucagon and gastric acid.
Involvement in mucosal secretory physiology has received negligible
attention. We aimed to study involvement of GLP-1 in mucosal
chloride secretion in the small intestine. Ussing chamber methods, in
concert with transmural electrical field stimulation (EFS), were used
to study actions on neurogenic chloride secretion. ELISA was used to
study GLP-1R effects on neural release of acetylcholine (ACh).
Intramural localization of GLP-1R was assessed with immunohisto-
chemistry. Application of GLP-1 to serosal or mucosal sides of
flat-sheet preparations in Ussing chambers did not change baseline
short-circuit current (Isc), which served as a marker for chloride
secretion. Transmural EFS evoked neurally mediated biphasic in-
creases in Isc that had an initial spike-like rising phase followed by a
sustained plateau-like phase. Blockade of the EFS-evoked responses
by tetrodotoxin indicated that the responses were neurally mediated.
Application of GLP-1 reduced the EFS-evoked biphasic responses in
a concentration-dependent manner. The GLP-1 receptor antagonist
exendin-(9–39) suppressed this action of GLP-1. The GLP-1 inhibi-
tory action on EFS-evoked responses persisted in the presence of
nicotinic or vasoactive intestinal peptide receptor antagonists but not
in the presence of a muscarinic receptor antagonist. GLP-1 signifi-
cantly reduced EFS-evoked ACh release. In the submucosal plexus,
GLP-1R immunoreactivity (IR) was expressed by choline acetyltrans-
ferase-IR neurons, neuropeptide Y-IR neurons, somatostatin-IR neu-
rons, and vasoactive intestinal peptide-IR neurons. Our results suggest
that GLP-1R is expressed in guinea pig submucosal neurons and that
its activation leads to a decrease in neurally evoked chloride secretion
by suppressing release of ACh at neuroepithelial junctions in the
enteric neural networks that control secretomotor functions.
gastrointestinal hormones; neurogenic chloride secretion; enteric ner-
vous system
GLUCAGON-LIKE PEPTIDE-1 (GLP-1) is a gut-derived hormone
released from L-type enteroendocrine cells after a meal (28). It
attracts interest because of its incretin effect, which results in
enhanced insulin secretion even before blood sugar levels
become elevated (4, 26). This suggests that it might be an
efficacious therapeutic agent in the treatment of diabetes mel-
litus (4, 28, 47). Moreover, GLP-1 has significant gastrointes-
tinal regulatory functions (26). It suppresses motility in general
(1, 32, 39, 44, 48) and retards gastric emptying (3, 32, 48) by
action in the antral pump (43) and gastric reservoir (2, 16).
GLP-1 inhibits gastric and pancreatic secretory functions in
humans (50) and inhibits gastric acid secretion evoked by
either pentagastrin or sham feeding (41, 45, 51). GLP-1 effec-
tively inhibits vagally evoked acid secretion but is ineffective
for hormonal stimulation (45, 51). Inhibition of acid secretion
by GLP-1 is lost after vagotomy, which would be consistent
with suppression acetylcholine (ACh) release from vagal ef-
ferent innervation of gastric parietal glands.
GLP-1 acts at a specific transmembrane G protein receptor,
the GLP-1 receptor (GLP-1R). Messenger RNA for GLP-1R is
expressed in nodose ganglia and in the gastrointestinal tract (8,
9, 27, 43). It is expressed by nitrergic neurons in the myenteric
plexus of mouse intestine (1). Nevertheless, detailed evaluation
of GLP-1R expression in the enteric nervous system (ENS) is
lacking. We aimed to identify the classes of neurons in the
submucosal plexus of guinea pig small intestine that express
GLP-1R.
Interest in the biological actions of GLP-1 has focused on
pancreatic endocrine and gastric secretion with little attention
given to a possible role for GLP-1 in neurogenic control of the
intestinal secretory glands. Our second aim was to study
actions of GLP-1 on neurally evoked mucosal secretion of
NaCl and H2O in guinea pig small intestine.
Neurogenic control of movement of NaCl, H2O and HCO3
into the intestinal lumen is basic for maintenance of physio-
logical osmolarity and pH and for understanding mechanisms
involved in diarrhea and constipation. The ENS, in concert
with the sympathetic division of the autonomic nervous sys-
tem, is responsible for neurogenic moment-to-moment control
of H2O and electrolyte transport across the mucosal epithelium
(15, 52, 54). Secretomotor neurons in the submucosal plexus,
which release ACh and vasoactive intestinal polypeptide (VIP)
at the neuroepithelial junctions, are the final motor pathways
from the ENS for control of secretion (14, 33, 42).
We investigated a putative role for GLP-1 in neurogenic
secretion. GLP-1 action on neurally evoked chloride secretion,
immunohistochemical localization of the GLP-1R in the sub-
mucosal plexus, and its influence on stimulus-evoked release
of ACh from secretomotor neurons were studied.
MATERIALS AND METHODS
Methods used in the present study are unchanged from those we
reported earlier for a closely similar study of GLP-2 (5). Conse-
quently, the presentation of methods summarizes and quotes from the
earlier article (5).
Tissue preparation. Male albino Hartley guinea pigs (300–400 g)
were killed instantly by stunning, followed by exsanguination from
the cervical vessels according to procedures reviewed and approved
by the Ohio State University Laboratory Animal Care and Use
Committee and United State Department of Agriculture inspectors.
Ileal segments were removed and maintained in ice-cold Krebs solu-
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tion containing (in mM) 120.9 NaCl, 5.9 KCl, 1.2 MgCl2, 1.2
NaH2PO4, 14.4 NaHCO3, 2.5 CaCl2, and 11.5 glucose.
Immunohistochemistry. Immunohistochemical methods were stan-
dard and essentially the same as reported in detail for our earlier study
of GLP-2 (5). Table 1 lists sources for primary and secondary
antibodies and the optimal dilutions used. Whole mounts of the
submucosal plexus were placed in PBS containing 10% normal
donkey serum and 0.3% Triton X-100 for 30 min at room temperature
to minimize nonspecific binding and increase tissue permeability and
were then incubated overnight at 4°C in primary antibodies for
GLP-1R or a mixture of primary antibodies for double labeling.
Competition with the control peptide (catalog no. LS-P1205; Lifespan
Biosciences) established antibody specificity for GLP-1R. The
GLP-1R antibody was preabsorbed with the control peptide for 2 h
and then used for immunohistochemical localization of the receptor.
After being washed with PBS, the tissues were incubated with a single
secondary antibody or a mixture of appropriate secondary antibodies
conjugated with fluorescein isothiocyanate (FITC) or indocarbocyanin
(Cy3) at room temperature for 1 h, followed by washing in PBS and
mounting with Vectashield (Vector, Burlingame, CA). Fluorescence
labeling was examined with a Nikon Eclipse 90i fluorescence micro-
scope (Nikon Instruments, Melville, NY). Photomicrographs were
acquired with a CoolSnap HQ2 monochrome digital camera and
MetaMorph software (Molecular Devices, Sunnyvale, CA), stored on
disk, and analyzed with MetaMorph. Images were minimally adjusted
for brightness and contrast with MetaMorph. Immunoreactivity (IR)
for the GLP-1R and enteric neurochemical codes and numbers of
double-labeled cells were assessed in randomly chosen ganglia situ-
ated throughout the preparations.
Ussing chamber methods. The muscularis externa, including the
myenteric plexus, was removed by microdissection to obtain flat-sheet
preparations for the Ussing chamber studies. The flat-sheet prepara-
tions of submucosa/mucosa and submucosal plexus were mounted
between halves of Ussing flux chambers, which had a total cross-
sectional area of 0.64 cm2. The tissues were bathed on both sides, with
10 ml of oxygenated (95% O2 and 5% CO2) Krebs solution, main-
tained at 37°C by circulation from a temperature-controlled water
bath. Each Ussing chamber had a pair of Ag-AgCl electrodes con-
nected through Krebs-agar bridges to calomel half-cells for the mea-
surement of transmural potential difference (PD). A second pair of
electrodes was connected to an automated voltage-clamp amplifier,
which was a source of short-circuit current (Isc) to maintain zero
potential difference between the PD-sensing bridges. Current strength
necessary for changing the transepithelial PD by 2.5 mV was used to
monitor tissue conductance as a determinant of tissue viability. Isc
(measured in A/cm2) was monitored by a voltage-clamp apparatus
(DVC-1000; World Precision Instruments, Sarasota, FL) and dis-
played with a chart recorder (Dash IV; Astro-Med, West Warwick,
RI). Electrical field stimulation (EFS) applied between pairs of alu-
minum foil electrodes placed on the submucosal surface of the tissue
at the intersection between the two halves of the Ussing chamber was
used to fire all submucosal neurons, including secretomotor neurons
(13). Grass SD 88 stimulators (Grass Instruments, Quincy, MA)
supplied current to the electrodes. The stimulus parameters were
stimulus strength, 1–5 mA; frequency, 10 Hz; pulse duration, 0.5 ms;
and total stimulation duration, 90 s. Changes in Isc during EFS were
quantified as the difference between the peak response and baseline Isc
before stimulation. Blockade of the EFS-evoked responses by tetro-
dotoxin (1 M) confirmed earlier findings and was evidence that the
responses were neurally mediated (13, 22, 30, 31).
Experimental protocol. The preparations equilibrated for 30 min at
37°C before application of EFS. Stimulation was then begun at 5-min
intervals and continued until reproducible responses were recorded.
Stimulation was continued to obtain control data and was then
repeated in the presence of progressively increasing concentrations of
GLP-1 (0.1 nM–1 M). Incubation time for each concentration was 5
min. Pharmacological analysis consisted of application of GLP-1 in
the presence of one of four different receptor antagonists: 1) the
GLP-1 receptor antagonist exendin-(9–39) (10 nM); 2) the muscarinic
receptor antagonist scopolamine (1 M); 3) the nicotinic receptor
antagonist hexamethonium (100 M), or 4) a selective VIP type I
antagonist, VPAC (1 M). Each agent was placed into the chamber 30
min before addition of GLP-1.
ACh release. Methods for measurement of EFS-evoked release of
ACh in Ussing chambers were similar to those of Yau et al. (55) and
Javed and Cooke (33), with the exception that these workers measured
release of [3H]ACh, whereas we determined ACh concentrations
using ELISA. Flat-sheet preparations were placed in Ussing chambers
with each half-chamber filled with agar to reduce the volume to 300
l. Electrode and fluid ports were blocked with agar. The preparations
were incubated with GLP-1 or GLP-1 followed by exendin-(9–39)
applied in combination for 30 min. Transmural EFS was applied in
each protocol. Contents of the chambers were collected immediately
at the end of stimulation and stored at20°C for subsequent analysis.
ACh concentration in each sample was determined by fluorescence
immunoassay (Amplex red acetylcholine/acetylcholinesterase assay
kit, catalog no. A12217; Invitrogen, Carlsbad, CA) and a fluorescence
microplate reader (SpectraMax M2; Molecular Devices). Fluores-
cence was measured with excitation at 560  10 nm and detection at
590  10 nm. ACh release was expressed as micrograms per square
centimeter of tissue.
Chemicals. The following reagents were used. Carbachol, scopol-
amine, and hexamethonium were purchased from Sigma (St Louis,
MO). GLP-1 and exendin-(9–39) were obtained from Tocris (Ellis-
ville, MO). The VPAC1 receptor antagonist [Ac-His1, D-Phe2, Lys15,
Arg16, Leu27]-VIP(3–7)-GRF(8–27) was obtained from Phoenix
Pharmaceuticals (Burlingame, CA).
Table 1. Codes and sources of primary and secondary antibodies used in the study
Antigen Host Code Dilution Source
Anti-Hu Mouse A21271 1:50 Molecular Probes
GLP-1R Rabbit LS-A1205 1:100 Lifespan Biosciences
ChAT Goat AB144P 1:100 Chemicon
NPY Sheep AB1583 1:1,500 Chemicon
Somatostatin Rat MAB354 1:200 Chemicon
VIP Sheep AB1581 1:1,000 Chemicon
Rabbit IgG Donkey Cy3 711-165-152 1:500 Jackson
Mouse IgG Donkey FITC 715-095-150 1:100 Jackson
Goat IgG Donkey FITC 705-095-003 1:100 Jackson
Sheep IgG Donkey FITC 713-095-147 1:100 Jackson
Rat IgG Donkey FITC AP189F 1:100 Chemicon
Anti-Hu, anti-human neuronal protein; GLP-1R, glucagon-like peptide-1 receptor; ChAT, choline acetyltransferase; NPY, neuropeptide Y; VIP, vasoactive
inhibitory peptide.
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Data analysis and statistics. Preparations from the same animal
were studied at the same time in four Ussing chamber setups. Data are
means  SE; n values refer to the number of animals. Statistical
significance was determined with paired Student’s t-test between
control and experimental populations or ANOVA followed by Bon-
ferroni post hoc test, when appropriate. Differences were considered
significant at P  0.05. Labeled neurons in 30 submucosal ganglia
were counted in the immunohistochemical studies. Total number of
neurons, labeled with a specific neuronal marker, and the percent
overlap of those markers with GLP-1R were determined.
RESULTS
Baseline Isc was 150  1.9 A/cm2 (n  18), and the
corresponding conductance was 37.2  1.2 mS/cm2. Applica-
tion of GLP-1 (0.1 nM–1 M) to the serosal side of the
preparations evoked no change in the baseline Isc (137.2  2.5
A/cm2, n  9, P  0.05) and did not alter the total tissue
conductance (34.7  2.2 mS/cm2, n  9, P  0.05).
Exposure to the muscarinic receptor agonist carbachol (10
M) evoked a maximal increase in Isc of 52.2  5.0 A/cm2
(n  3) within 3 min. Responses to carbachol were unaffected
by application of 10 nM GLP-1 (50.9  6.9, n  3, P  0.05).
Transmural EFS. Transmural EFS evoked biphasic in-
creases in Isc, which consisted of a spike-like rapid rise (phase
1) followed by a second, sustained phase 2 plateau-like re-
sponse (Fig. 1A). No significant “rundown” of the stimulus-
evoked responses appeared during 30 min following equilibra-
tion of the responses (Fig. 1B). GLP-1 (0.1 nM–1 M), placed
in the serosal side of the chamber, evoked concentration-
dependent reductions in both phase 1 and phase 2 of the
EFS-evoked responses (Figs. 1 and 2). This action of GLP-1
was suppressed following placement of the GLP-1R antagonist
exendin-(9–39) (10 nM) in the chambers (Fig. 2).
Exposure to 1 M scopolamine, a muscarinic receptor
antagonist, alone abolished phase 1 and significantly reduced
Fig. 1. Biphasic responses to electrical field stimulation
are suppressed by glucagon-like peptide-1 (GLP-1) in a
concentration-dependent manner. A: concentration-de-
pendent attenuation of stimulus-evoked biphasic re-
sponses. B: consecutive responses evoked over 30 min
served as controls. Stimulus parameters: 1–5 mA, 10
Hz, pulse width 0.5 ms, duration 90 s.
Fig. 2. The GLP-1 receptor antagonist exendin-(9–39),
at 10 nM, inhibited the action of GLP-1 to suppress both
phase 1 and phase 2 of electrical field stimulation of
chloride secretion. A: action of exendin-(9–39) on stim-
ulus-evoked phase 1. B: action of exendin-(9–39) on
stimulus-evoked phase 2. Data are means  SE for
preparations from 5 animals. *P  0.05 for exendin-
(9–39) relative to GLP-1 alone.
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phase 2 of the EFS-evoked responses. In the presence of
scopolamine, GLP-1 (0.1 nM–1 M) failed to modify further
the EFS-evoked secretory responses (Fig. 3A).
Application of the nicotinic receptor antagonist hexametho-
nium (100 M) in the bathing medium on the serosal side of
the preparation reduced both phase 1 and phase 2 of the
EFS-evoked responses. In the presence of hexamethonium,
GLP-1, in a concentration range from 0.1 nM to 1 M,
continued to inhibit the first and second phases of the EFS-
evoked secretory responses (Fig. 3B).
The presence of the VIP receptor antagonist VPAC1 (1 M)
in the bathing medium on the serosal side of the preparation did
not modify phase 1 but reduced significantly phase 2 of the
EFS-evoked responses. In the presence of VPAC1, GLP-1 (0.1
nM–1 M) continued to suppress both the first and second
phases of the secretory responses (Fig. 3C). Suppression of
phase 2 of EFS-evoked Isc by VIP receptor antagonists is
accepted as evidence that phase 2 is mediated in part by release
of VIP from secretomotor neurons at intestinal neuroepithelial
junctions (14, 42). We confirmed that incubation with VPAC1,
before placement of VIP in the Ussing chambers, suppressed
VIP-evoked increases in Isc (data not shown).
ACh release. Because functional data suggest that GLP-1
acts to suppress release of ACh from secretomotor neurons at
their junctions with the epithelium, we measured the amount of
ACh released from the submucosal/mucosal preparations
evoked by EFS in the absence or presence of GLP-1 to test the
hypothesis further. GLP-1 (10 nM) significantly reduced the
amount of EFS-evoked ACh release (Fig. 3D). Pretreatment
with 10 nM exendin-(9–39) reversed the action of GLP-1 to
suppress stimulus-evoked release of ACh (Fig. 3D).
Immunofluorescence. IR for the GLP-1R in the submucosal
plexus was localized to the cytoplasm of the neurons (Fig. 4).
GLP-1R-IR was colocalized with IR for the protein, Hu, in
over 50% of the neurons (Fig. 4, A1–A3). The nuclear protein
Hu is part of a family of conserved RNA-binding proteins that
includes HuC, HuD, and HuR (49). It is a useful immunohis-
tochemical tool because it labels all ENS neurons (36). No IR
fluorescence was seen when the GLP-1R antibody was pread-
sorbed with its control peptide (not shown).
Application of double-labeling immunofluorescence meth-
ods showed that GLP-1R colocalized with 66.91  4.3% (n 
4) of neurons that expressed choline acetyltransferase-IR
(ChAT-IR) (Fig. 4, B1–B3) and with 60.60  6.2% (n  3) of
neuropeptide Y-IR (NPY-IR) neurons (Fig. 4, C1–C3). GLP-
1R-IR was coexpressed with somatostatin-IR in 54.8  6.6%
(n  4) of the neurons (Fig. 4, D1–D3). GLP-1R-IR colocal-
ized VIP-IR in 42.0  7.8% (n  3) of the neurons (Fig. 4,
E1–E3).
DISCUSSION
GLP-1 influences gastric, insulin, and glucagon secretion
(29, 40, 41, 45, 50, 51). Our results suggest, for the first time,
that GLP-1 might also be involved in intrinsic neuroendocrine
signaling that regulates mucosal secretion of electrolytes, H2O,
and mucus and, therefore, luminal liquidity, pH, and protection
in the small intestine.
Transmucosal EFS. Finding of no effect of GLP-1 on
baseline Isc and conductance indicates a lack of direct action on
epithelial ion transport, per se. Instead, GLP-1 suppression of
EFS-evoked Isc suggests inhibition of neurogenic chloride
secretion. This action appeared to be receptor mediated be-
cause it was concentration dependent and suppressed by exen-
din-(9–39), which is a potent GLP-I receptor antagonist and a
valuable tool for investigating the actions of GLP-I (21).
Fig. 3. Pharmacological analysis of GLP-1
action on phases 1 and 2 of short-circuit cur-
rent (Isc) responses to electrical field stimula-
tion and evoked release of acetylcholine
(ACh). A: the muscarinic receptor antagonist
scopolamine suppressed phase 1 to a greater
extent than phase 2. GLP-1 suppressed phase
1 to a greater extent than phase 2. No suppres-
sion of phase 2 by GLP-1 occurred in the
presence of scopolamine. B: the nicotinic re-
ceptor antagonist hexamethonium (C6) sup-
pressed both phase 1 and phase 2. Application
of GLP-1 in the presence of C6 decreased
further the amplitude of phase 1 and phase 2
responses. C: the vasoactive intestinal peptide
(VIP) receptor antagonist VPAC1 suppressed
phase 2 but not phase 1 responses. Suppres-
sion by GLP-1 was unaffected by the presence
of VPAC1. D: the GLP-1 receptor antagonist
exendin-(9–39) suppressed inhibition of stim-
ulus-evoked ACh by GLP-1. Data are
means  SE for preparations from 6 animals.
Concentrations: GLP-1, 10 nM; scopolamine,
1 M; C6, 100 M; VPAC1, 1 M; exendin-
(9–39), 10 nM. *P  0.05 for GLP-1 relative
to control. #P 0.05 for GLP-1 relative to C6
or VPAC1. #P  0.05 for GLP-1 relative to
exendin (9–39).
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Blockade of GLP-1R by exendin-(9–39) changed neither base-
line Isc nor EFS-evoked responses, which suggests that GLP-1
has no direct action on enterocytes or paracellular conduction
pathways. Moreover, it suggests absence of any spontaneous
release of GLP-1 from intramural sources in the preparations in
vitro.
The carbachol-evoked responses reflect direct stimulation of
muscarinic receptors on enterocytes, because the responses are
not suppressed by neural blockade with tetrodotoxin and are
blocked by the muscarinic antagonist scopolamine (see Fig.
3A) (12, 33). Lack of effect of GLP-1 on carbachol-evoked
stimulation of Isc suggests that GLP-1 inhibitory action on
EFS-evoked Isc took place at submucosal secretomotor neurons
and/or at other ENS neurons that provided excitatory synaptic
input to the secretomotor neurons.
The EFS evoked biphasic increases in Isc in the current study
were typical of earlier reports (13, 20). They mimicked obser-
vations in a variety of other species, including mice (11),
rabbits (30), and humans (31). The biphasic responses in
guinea pig flat-sheet preparations reflect release of multiple
neurotransmitters from secretomotor neurons and release of
transmitters from interneurons that supply excitatory synaptic
input to the secretomotor neurons. ACh and VIP are the main
neurotransmitters released by the secretomotor neurons. The
action of ACh is at epithelial muscarinic M3 receptors and
signal transduction involves elevation of cytosolic Ca2 in the
enterocytes and activation of protein kinase C (12, 17, 18, 38).
Signal transduction for VIP differs from ACh. It involves
stimulation of adenylyl cyclase, elevation of cAMP, and stim-
ulation of PKA in the enterocytes (19, 46). Phase 1 of the
EFS-evoked response in the guinea pig is mediated mainly, if
not solely, by the release of ACh. Phase 2 has a peptidergic
component that includes VIP as a major contributor (14, 15).
Our protocol was to evoke the biphasic increases in Isc, add
GLP-1 in the serosal compartment of the chamber, and reapply
EFS. Results obtained with this protocol support a hypothesis
that phase 1 of the EFS-evoked responses is mediated primarily
by secretomotor release of ACh and that phase 2 includes a
component of VIP release in parallel with ACh. Our data
suggest that GLP-1 acts to suppress the cholinergic component
in both phases 1 and 2 with marginal, if any, effect on VIP
release. Consistent with this was the finding that GLP-1 did not
further suppress phase 2 after blockade of the cholinergic
component by scopolamine. Moreover, when the VIPergic
component of phase 2 was suppressed by the selective VIP
antagonist VPAC1, exposure to GLP-1 still reduced the phase
2 response. When considered in view of the results showing no
effect of GLP-1 on Isc after neural blockade by tetrodotoxin,
these results suggest that the action of GLP-1, to suppress
EFS-evoked secretion, reflects inhibition of presynaptic/
prejunctional release of ACh by ENS neurons.
EFS, when applied to mucosal preparations in Ussing cham-
bers, fires most all of the cell bodies of all classes of ENS
neurons in the preparations and therefore their axonal output
either to synapses on cell bodies of neighboring neurons or at
neuroeffector junctions (10). Blockade by hexamethonium
(i.e., C6) of nicotinic synaptic connections among neighboring
neurons in the ENS microcircuitry partially suppressed both
phases 1 and 2 of the EFS-evoked responses (see Fig. 3). The
responses, remaining after nicotinic blockade, reflected direct
stimulation of secretomotor neurons and release of ACh at the
neuroepithelial junctions. Suppression of the residual re-
sponses by GLP-1 suggests inhibition of ACh release at the
neuroepithelial junctions. Together, these results support the
overall conclusion that GLP-1 acts to inhibit ACh release at
synaptic connections between ENS neurons and at the junc-
tions of secretomotor neurons with the epithelium.
Immunofluorescence. Our immunofluorescence results for
localization of GLP-1R in the submucosal plexus are consistent
with a conclusion that GLP-1R suppresses neurogenic secre-
tion by inhibiting neuronal ACh release. Neuronal cell bodies,
which expressed ChAT-IR, NPY-IR, somatostatin-IR, or VIP-
IR, all expressed GLP-1R-IR. ChAT-IR and NPY-IR, in the
same neuron, is a neurochemical code for the class of secre-
tomotor neurons that do not send collaterals to innervate
periglandular arterioles (25, 54). ChAT-IR neurons that contain
Fig. 4. Expression of immunoreactivity (IR) for the GLP-1 receptor (GLP-1R) in
whole mounts of guinea pig small intestinal submucosal plexus. A1–A3: coexpres-
sion of GLP-1R-IR with anti-Hu-IR, which marks all enteric neurons, reveals
expression of GLP-1R-IR restricted to neuronal cell bodies. B1–B3: coexpression
of GLP-1R-IR with choline acetyltransferase (ChAT)-IR, which is a neurochem-
ical marker for cholinergic secretomotor neurons. C1–C3: coexpression of GLP-
1R-IR with neuropeptide Y (NPY)-IR, which is a neurochemical marker for
secretomotor/nonvasodilator motor neurons when coexpressed with ChAT-IR.
D1–D3: coexpression of GLP-1R-IR with somatostatin-IR, which is a neurochem-
ical marker for interneurons that provide inhibitory input to secretomotor neurons.
E1–E3: coexpression of GLP-1R-IR with VIP-IR, which is a neurochemical
marker for noncholinergic secretomotor/vasodilator motor neurons. Scale bars,
20 m.
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calretinin are cholinergic secretomotor/vasodilator neurons (7,
25). VIP-IR is a marker for noncholinergic secretomotor/
vasodilator neurons that receive sympathetic noradrenergic
inhibitory input. Somatostatin-IR identifies interneurons in the
ENS that supply inhibitory synaptic input to secretomotor
neurons (23, 37). Expression of GLP-1R by cholinergic secre-
tomotor/nonvasodilator neurons and cholinergic secretomotor/
vasodilator neurons can account for suppression of the cholin-
ergic component of EFS-evoked phases 1 and 2 of the secre-
tory responses when GLP-1 was present in the tissue chamber.
Expression of GLP-1R by noncholinergic secretomotor/va-
sodilator neurons is inconsistent with our finding that GLP-1
had little or no effect on the VIPergic component of the
stimulus-evoked phase 2 response. The discrepancy might be
explained by the existence of VIPergic secretomotor neurons
known to evoke mucosal HCO3 secretion (34). Expression of
GLP-1R by the neurons that contained VIP might be a reflec-
tion of differences in parallel neural pathways, one for Cl
secretion and the other for HCO3.
ACh release. Cholinergic neurons make up about 50% of the
submucosal neurons in the guinea pig small intestine (6, 24).
Finding that GLP-1R was expressed by cholinergic secretomo-
tor neurons suggests a neuronal action for GLP-1. This and
finding that suppression of EFS-evoked biphasic increases in
Isc by GLP-1 or a muscarinic receptor antagonist lead us to
suggest that the action of GLP-1 on neurogenic Cl secretion
is suppression of neuronal release of ACh. Finding that GLP-1
suppressed stimulus-evoked ACh release and suppression of
this action by a selective GLP-1R antagonist supports the
suggestion.
Suppression of EFS-evoked ACh release could result from
an inhibitory action of GLP-1 on the excitability of cholinergic
secretomotor neurons, or it could result from binding at inhib-
itory presynaptic/prejunctional GLP-1Rs at axonal ACh release
sites. Intracellular electrophysiological recording of GLP-1
action on electrical and synaptic behavior in submucosal neu-
rons will be necessary to clarify the specific mechanism by
which GLP-1 suppresses ACh release in the ENS.
Physiological significance of the action of GLP-1 in the
small intestine is suggested to be a mechanism involved in
minute-to-minute adjustment of the output of cholinergic se-
cretomotor/vasodilator neurons. By adjusting secretomotor/
vasodilator output, the negative feedback control networks in
the ENS can regulate the osmolarity of the intraluminal milieu
and thereby contribute to maintenance of an optimal environ-
ment for pancreatic and brush border digestive enzymes to
work as digestion proceeds.
Conclusion. Cholinergic neurons, including secretomotor
neurons, in the submucosal plexus of guinea pig small intestine
express receptors for GLP-1. Stimulation of the GLP-1 recep-
tors suppresses mucosal Cl secretion evoked by electrical
stimulation of neurons in the submucosal plexus. Suppression
of mucosal Cl secretion results from GLP-1 action to atten-
uate release of ACh from secretomotor neurons.
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